Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Total Current Liabilities (2023 - 2025)

Zenas BioPharma has reported Total Current Liabilities over the past 3 years, most recently at $62.6 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $62.6 million for Q4 2025, up 9.35% from a year ago — trailing twelve months through Dec 2025 was $62.6 million (up 9.35% YoY), and the annual figure for FY2025 was $62.6 million, up 9.35%.
  • Total Current Liabilities for Q4 2025 was $62.6 million at Zenas BioPharma, up from $52.4 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for ZBIO hit a ceiling of $62.6 million in Q4 2025 and a floor of $23.3 million in Q4 2023.
  • Median Total Current Liabilities over the past 3 years was $52.4 million (2025), compared with a mean of $48.9 million.
  • Biggest five-year swings in Total Current Liabilities: skyrocketed 146.33% in 2024 and later grew 9.35% in 2025.
  • Zenas BioPharma's Total Current Liabilities stood at $23.3 million in 2023, then skyrocketed by 146.33% to $57.3 million in 2024, then increased by 9.35% to $62.6 million in 2025.
  • The last three reported values for Total Current Liabilities were $62.6 million (Q4 2025), $52.4 million (Q3 2025), and $53.2 million (Q2 2025) per Business Quant data.